Helaba Selects Quantifi xVA Platform for Counterparty Risk Management

German bank replaces in-house xVA solution for counterparty risk mitigation and management.

frankfurt-sunrise-1-vertical-web
Based in Frankfurt, Helaba held €180 billion in assets under management in 2014.

With an increasing regulatory burden placed on risk mitigation and reporting, Helaba opted to replace its legacy xVA system ─ encompassing credit value adjustment (CVA), debt valuation adjustment (DVA) and funding value adjustment (FVA) calculations ─ with Quantifi's integrated trading, analytics and reporting solution, which covers xVA, IFRS13, EMIR, Mifid II, CRD IV, the Dodd-Frank Act and Basel lll, with particular focus on the bank's OTC derivatives business.

"The complexity in all aspects of counterparty risk management has driven Helaba to replace its in-house xVA risk solution with a technology partner that is both capable and committed to addressing the needs of this market," says Matthias Rapp, head of trading at Helaba. "To mitigate risk, enhance transparency, and increase capital efficiency, we need a more dynamic system that can provide consistent analytics and a single view of xVA risk across our entire portfolio of vanilla and exotic instruments."

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

DORA stalls over identifier dispute

A disagreement over how to classify third-party tech providers on a reporting form known as the “register of information” has held up preparations for the highly anticipated operational resiliency rule in Europe.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here